Beta2-Glycoprotein-1 IgM EULISA - Discontinued

The EULISA ß2-Glycoprotein-1 IgM is intended for determination of IgM antibodies against ß2-Glycoprotein in human serum. The occurrence of these antibodies is associated with anti-phospholipid syndrome (APS), an autoimmune disorder characterised by thrombosis in both arteries and veins. Antibodies against ß2-Glycoprotein are also believed to be directly involved in the pathogenesis of APS.

Intended use

Enzyme immunoassay for the detection of autoantibodies IgM against ß2-Glycoprotein-1.

Background

The anti-phospholipid syndrome (APS) is an autoimmune disorder which can comprise clinical conditions such as venous and arterial thrombosis, thrombocytopenia, myocardial infarction, recurrent spontaneous abortion and neurological complications.

Cardiolipin (CL) is a common, negatively charged, acid phospholipid. Autoantibodies associated with APS are directed not only against CL and similar phospholipides but also against phospholipid/protein complexes. ß2-glycoprotein 1 (ß2-GP-1; = apolipoprotein H) has been identified as a natural and essential co-antigen for CL-autoantibodies. The occurrence of CL/ß2-GP-1 autoantibodies is associated with a tendency towards thrombosis.

Technical information

The EULISA ß2-Glycoprotein-1 IgM is intended for the quantitative or qualitative determination of IgM antibodies in human serum, directed against ß2-GP-1. The immobilised antigen is a highly purified preparation of human ß2-GP-1.

The test is fast (incubation time 30-30-30 minutes) and flexible (break apart wells, ready-to-use reagents). Six calibrators allow quantitative measurements; a negative and a positive control are used to check assay performance.

Kit components and storage of reagents

Contents of the kit

1 microwell plate, coated with ß2-GP-1 and hermetically packed in a foil laminate pouch together with a desiccant bag.